Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 30 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Bleeding Active Clear all
Completed Phase 3 Interventional Results available

Reversal of Dabigatran Anticoagulant Effect With Idarucizumab

NCT02104947
View directory record Official record
Conditions
Hemorrhage
Interventions
idarucizumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
503 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
30
States / cities
Little Rock, Arkansas • Loma Linda, California • Washington D.C., District of Columbia + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2018 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Outcomes and Safety Trial Investigating Ecallantide's Effect on Reducing Surgical Blood Loss Volume in Subjects at High Risk of Bleeding Exposed to Cardio-pulmonary Bypass During Cardiac Surgery

NCT00888940
View directory record Official record
Conditions
Bloodloss, Surgical Procedures, Operative
Interventions
Ecallantide, Cyklokapron(R)
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 9, 2015 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Active Versus Expectant Management of the Third Stage of Labor

NCT00473707
View directory record Official record
Conditions
Postpartum Hemorrhage
Interventions
Active management of the third stage of labor, Expectant management of the third stage of labor, Oxytocin and gentle cord traction with fundal massage, Oxytocin
Procedure · Drug
Lead sponsor
Christiana Care Health Services
Other
Eligibility
16 Years and older · Female only
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 11, 2023 · Synced Jul 22, 2026, 9:09 AM EDT
Active, not recruiting No phase listed Observational

REpeated ASSEssment of SurvivorS in Intracerebral Hemorrhage Study

NCT05611918
View directory record Official record
Conditions
Intra Cerebral Hemorrhage, ICH - Intracerebral Hemorrhage, ICH, Hemorrhage, Stroke, Clot (Blood); Brain, Clot Blood, Cognitive Decline, Cognitive Impairment, Survivorship, Memory Impairment, Motor Activity
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Birmingham, Alabama • La Jolla, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 9:09 AM EDT
Terminated Phase 1Phase 2 Interventional

Transcranial Ultrasound in Clinical SONothrombolysis

NCT00504842
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
MRX-801, Placebo
Drug
Lead sponsor
ImaRx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2008 · Synced Jul 22, 2026, 9:09 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

NCT04755283
View directory record Official record
Conditions
Atrial Fibrillation (AF), Stroke
Interventions
Abelacimab, Rivaroxaban
Biological · Drug
Lead sponsor
Anthos Therapeutics, Inc.
Industry
Eligibility
55 Years and older
Enrollment
1,287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
28
States / cities
Huntsville, Alabama • Mobile, Alabama • Stamford, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 22, 2026, 9:09 AM EDT
Completed No phase listed Observational

A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors

NCT01830712
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
eptacog alfa (activated)
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Jul 22, 2026, 9:09 AM EDT
Completed No phase listed Observational

Platelet Activity in Vascular Surgery for Thrombosis and Bleeding

NCT01897103
View directory record Official record
Conditions
Peripheral Vascular Disease, Peripheral Artery Disease, Carotid Stenosis, Aortic Aneurysm, Abdominal, Aortic Aneurysm, Thoracic, Amputation, Wound, Embolism and Thrombosis, Aortic Aneurysm
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Jul 22, 2026, 9:09 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Induced Suppression of Platelet Activity in Aneurysmal Subarachnoid Hemorrhage Management-2 (iSPASM-2)

NCT07493577
View directory record Official record
Conditions
Aneurysmal Subarachnoid Hemorrhage
Interventions
Tirofiban, Placebo
Drug
Lead sponsor
Dr David Hasan, M.D.
Other
Eligibility
18 Years to 85 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
2
States / cities
Durham, North Carolina • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 9:09 AM EDT
Terminated Phase 4 Interventional Results available

Residual Anti-Xa Activity After Last Treatment Dose of Enoxaparin

NCT03296033
View directory record Official record
Conditions
Anticoagulants and Bleeding Disorders, Surgery, Regional Anesthesia Morbidity
Interventions
Enoxaparin
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 100 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jul 22, 2026, 9:09 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

NCT01433978
View directory record Official record
Conditions
Idiopathic Thrombocytopenic Purpura
Interventions
Eltrombopag, Avatrombopag, Standard of care
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Watertown, South Dakota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Results available

A Study of Safety and Efficacy of Fibrin Sealant Grifols as an Adjunct to Haemostasis During Surgery in Paediatric Participants

NCT03461406
View directory record Official record
Conditions
Excessive Bleeding During Surgery
Interventions
Fibrin Sealant Grifols, EVICEL
Biological
Lead sponsor
Instituto Grifols, S.A.
Industry
Eligibility
Up to 17 Years
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
12
States / cities
Chicago, Illinois • Michigan Center, Michigan • Albany, New York + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 3 Interventional

Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

NCT03938792
View directory record Official record
Conditions
Hemophilia A, Hemophilia B
Interventions
PF-06741086
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 74 Years · Male only
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Tampa, Florida • Iowa City, Iowa • New Hyde Park, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2025 · Synced Jul 22, 2026, 9:09 AM EDT
Not listed No phase listed Observational

Low VW Activity in Adolescent HMB

NCT02933411
View directory record Official record
Conditions
Von Willebrand Factor Deficiency
Interventions
Genetic Analysis, Medical Record Data Abstraction, Pictorial Blood Assessment Chart (PBAC) score, Complete Bleeding Symptom ISTH Bleeding Assessment Tool
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 21 Years · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
12
States / cities
Atlanta, Georgia • East Lansing, Michigan • Kansas City, Missouri + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Jul 22, 2026, 9:09 AM EDT
Recruiting Not applicable Interventional

AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis

NCT05649904
View directory record Official record
Conditions
Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, Ventriculitis
Interventions
IRRAflow with Active Fluid Exchange System, External Ventricular Drain
Device
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 2 Interventional Results available

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

NCT00961532
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
DDAVP injection (desmopressin acetate)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Results available

Active-control Randomized Trial Comparing 4-factor Prothrombin Complex Concentrate With Frozen Plasma in Cardiac Surgery

NCT05523297
View directory record Official record
Conditions
Bleeding Cardiac Surgery Patients
Interventions
Octaplex, Frozen Plasma Product, Human
Drug
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Aug 14, 2025 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Induced Suppression of Platelets Activity in Aneurysmal SAH Management (iSPASM)

NCT03691727
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal
Interventions
tirofiban hydrochloride (AGGRASTAT®), MRI, Neurological Exam, Questionnaires, Vital Signs, Standard of Care Treatment
Drug · Diagnostic Test · Behavioral + 1 more
Lead sponsor
David Hasan
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

NCT02141074
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia B
Interventions
nonacog beta pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
0 Years to 6 Years · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Gainesville, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 2 Interventional

Study of Recombinant Porcine Factor VIII (FVIII) in Hemophilia and Inhibitors to FVIII

NCT00245245
View directory record Official record
Conditions
Hemophilia A
Interventions
recombinant porcine coagulation factor VIII (OBI-1)
Drug
Lead sponsor
Octagen Corporation
Industry
Eligibility
12 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Blue Bell, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 3, 2007 · Synced Jul 22, 2026, 9:09 AM EDT
Recruiting Not applicable Interventional

Aphasia Physical EXercise Study: Randomized Trial

NCT07281313
View directory record Official record
Conditions
Aphasia, Acquired, Aphasia, Aphasia, Fluent, Aphasia, Non-fluent, Aphasia Following Cerebral Infarction, Aphasia Following Nontraumatic Intracerebral Hemorrhage
Interventions
High-intensity physical exercise, Low-intensity physical exercise
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
4
States / cities
Berkeley, California • Hayward, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Jul 22, 2026, 9:09 AM EDT
Recruiting Phase 2 Interventional

Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

NCT07032792
View directory record Official record
Conditions
Cardiac Disease, Surgery, Bleeding
Interventions
FEIBA, FFP
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Jul 22, 2026, 9:09 AM EDT
Completed No phase listed Observational

Prevention of Retained-Blood Outcomes With Active Clearance Technology

NCT02145858
View directory record Official record
Conditions
Hemorrhage, Atrial Fibrillation, Postoperative
Interventions
Blood drainage post cardiac surgery using PleuraFlow System
Device
Lead sponsor
ClearFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
891 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
2
States / cities
Manchester, New Hampshire • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Jul 22, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis

NCT02195986
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream, Placebo Vaginal Cream
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
366 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2022 · Synced Jul 22, 2026, 9:09 AM EDT